Abametapir
 | |
| Clinical data | |
|---|---|
| Trade names | Xeglyze |
| Other names | Ha44 |
| AHFS/Drugs.com | Xeglyze |
| License data |
|
| Routes of administration | Topical |
| Drug class | Pediculicide, Metalloproteinase inhibitor |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.157.434 |
| Chemical and physical data | |
| Formula | C12H12N2 |
| Molar mass | 184.242 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Abametapir, sold under the brand name Xeglyze, is a medication used for the treatment of head lice infestation in people six months of age and older.[1][2]
The most common side effects include skin redness, rash, skin burning sensation, skin inflammation, vomiting, eye irritation, skin itching, and hair color changes.[2]
Abametapir is a metalloproteinase inhibitor.[1] Abametapir was approved for medical use in the United States in July 2020.[1][3]
Medical uses
Abametapir is indicated for the topical treatment of head lice infestation in people six months of age and older.[1][2]
History
The U.S. Food and Drug Administration (FDA) approved abametapir based on evidence from two identical clinical trials of 699 participants with head lice.[2] The trials were conducted at fourteen sites in the United States.[2]
The benefit and side effects of abametapir were evaluated in two clinical trials that enrolled participants with head lice who were at least six months old.[2]
About half of all enrolled participants was randomly assigned to abametapir and the other half to placebo.[2] Abametapir lotion or placebo lotion were applied once as a ten-minute treatment to infested hair.[2] The benefit of abametapir in comparison to placebo was assessed after 1, 7 and 14 days by comparing the counts of participants in each group who were free of live lice.[2]
References
- ^ a b c d e "Xeglyze (abametapir) lotion, for topical use" (PDF). U.S. Food and Drug Administration (FDA). Dr. Reddy's Laboratories. Inc. Retrieved 25 July 2020.
- ^ a b c d e f g h i "Drug Trial Snapshot: Xeglyze". U.S. Food and Drug Administration (FDA). 24 July 2020. Retrieved 6 August 2020.
This article incorporates text from this source, which is in the public domain.
- ^ "Abametapir: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 July 2020.
Further reading
- Bowles VM, VanLuvanee LJ, Alsop H, Hazan L, Shepherd K, Sidgiddi S, et al. (September 2018). "Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation". Pediatr Dermatol. 35 (5): 616–621. doi:10.1111/pde.13612. PMC 6175393. PMID 29999197.
External links
- "Abametapir". Drug Information Portal. U.S. National Library of Medicine.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |